Arginine Nutrition and Cardiovascular Function

Guoyao Wu and Cynthia J. Meininger

*Department of Animal Science and Faculty of Nutrition, Texas A&M University, and †Cardiovascular Research Institute and Department of Medical Physiology, The Texas A&M University System Health Science Center, College Station, TX 77843

ABSTRACT L-Arginine (Arg) is the substrate for the synthesis of nitric oxide (NO), the endothelium-derived relaxing factor essential for regulating vascular tone and hemodynamics. NO stimulates angiogenesis, but inhibits endothelin-1 release, leukocyte adhesion, platelet aggregation, superoxide generation, the expression of vascular cell adhesion molecules and monocyte chemotactic peptides, and smooth muscle cell proliferation. Arg exerts its vascular actions also through NO-independent effects, including membrane depolarization, syntheses of creatine, proline and polypeptides, secretion of insulin, growth hormone, glucagon and prolactin, plasmin generation and fibrinogenolysis, superoxide scavenging and inhibition of leukocyte adhesion to nonendothelial matrix. Compelling evidence shows that enteral or parenteral administration of Arg reverses endothelial dysfunction associated with major cardiovascular risk factors (hypercholesterolemia, smoking, hypertension, diabetes, obesity/insulin resistance and aging) and ameliorates many common cardiovascular disorders (coronary and peripheral arterial disease, ischemia/reperfusion injury, and heart failure). Dietary Arg supplementation may represent a potentially novel nutritional strategy for preventing and treating cardiovascular disease.


KEY WORDS: • arginine • cardiovascular disease

As a precursor for synthesis of nitric oxide (NO), ornithine, proline, polyamines, creatine, agmatine and protein, and as an allosteric activator of N-acetylglutamate synthase, L-arginine (Arg) plays vital roles in nutrition and metabolism. On the basis of growth or nitrogen balance, Arg is classified as an essential amino acid for birds, carnivores and young mammals, and as a conditionally essential amino acid for mammals, and as a conditionally essential amino acid for birds, carnivores and young mammals, and as a conditionally essential amino acid for mammals. Although extracellular Arg is the major source of the Arg for endothelial NO synthesis, intracellular Arg degradation or the Arg-citrulline cycle may provide Arg for supporting short-term basal NO production by EC when extracellular Arg is limited. Thus, Arg may be saturated with intracellular Arg and that endothelial NO synthesis may not respond to alterations in extracellular Arg concentrations. However, increasing extracellular Arg concentrations from 0.1 to 10 mmol/L in a dose-dependent manner increases NO production by cultured EC (5), and elevating plasma Arg levels enhances systemic and vascular NO production in vivo (4,6). A number of theories have been proposed to explain this Arg paradox, including colocalization of Arg transporter (CAT-1) and eNOS in membrane-associated caveolae, intracellular compartmentation of Arg, interaction between Arg and glutamine, alterations in eNOS dimerization and competitive inhibition of eNOS by endogenous inhibitors [e.g., asymmetric dimethylarginine (ADMA)] (4,5). Nevertheless, compelling evidence indicates that increasing extracellular Arg drives endothelial NO production (1,4).

NO-dependent and independent effects of Arg. Arg, a substrate for eNOS, is essential for maintaining the enzyme in the active dimerization state (5). In blood vessels, endothelium-derived NO activates guanylyl cyclase to generate cGMP from GTP in smooth muscle cells, elevates cellular cGMP concentrations and causes smooth muscle relaxation (3). Thus, NO plays an essential role in regulating vascular tone

1 Supported by grants from the American Heart Association (AHA) and Juvenile Diabetes Foundation. G.W. is an Established Investigator of the AHA.
2 Manuscript received 31 July 2000.
3 To whom correspondence should be addressed.
4 Abbreviations used: ADMA, asymmetric dimethylarginine; Arg, L-arginine; CAD, coronary artery disease; CHF, congestive heart failure; EC, endothelial cells; eNOS, endothelial NO synthase; NO, nitric oxide; PAD, peripheral arterial disease.
and hemodynamics. NO stimulates EC proliferation and angiogenesis, thereby playing an important role in wound healing and microcirculation (7). In addition, NO inhibits the release of endothelin-1 (a vasoconstrictor) by EC, leukocyte adhesion to the endothelium, platelet aggregation, superoxide generation by NADPH oxidase, the expression of vascular cell adhesion molecules and monocyte chemotactic peptides, and the proliferation of smooth muscle cells (3,4). NO also inhibits apoptosis in EC possibly through two mechanisms: 1) increasing cGMP generation, which interrupts apoptotic signaling, and 2) directly inhibiting cysteine protease (caspase) activity (8). Thus, in addition to its effect on vasorelaxation and angiogenesis, NO is a novel antiatherogenic, antiproliferative and antithrombotic factor.

Although the vascular effects of Arg are mediated primarily by NO production (4), Arg also exerts NO-independent hemodynamic effects (Table 1). As a basic amino acid, Arg may contribute to the depolarization of EC membranes and regulate blood and intracellular pH. As an antioxidant, Arg (0.5–1 mmol/L) can scavenge O₂⁻, reduce copper-induced lipid peroxidation and inhibit O₂⁻ release by EC (9). As a possible regulator of the binding of macromolecules to RBC, high Arg concentrations (≥2.5 mmol/L) decrease blood viscosity (10). As a precursor for the synthesis of protein, urea, creatine, polyamines, proline, glutamate and agmatine, Arg plays vital roles in nutrition and physiology (1). For example, creatine participates in energy metabolism in muscle and nerves, polyamines are crucial to cell proliferation and differentiation, and proline is critical to collagen synthesis and thus extracellular matrix formation and vessel remodeling. As an allosteric activator of N-acetylglutamate synthase to synthesize N-acetyl-glutamate (an essential cofactor for carbamoylphosphate synthase I), Arg maintains the urea cycle in the active state for ammonia detoxification (1). As a stimulator of the secretion of insulin, growth hormone, glucagon and prolactin, Arg regulates the metabolism of glucose, protein and lipids, factors that are closely linked to atherogenesis (4). As an inhibitor of angiotensin-converting enzyme, Arg reduces plasma angiotensin II levels and thus amplifies its hypotensive effect (11). Through inhibiting the formation of thromboxane B₂ and the platelet-fibrin complex while enhancing plasmin generation and fibrin degradation, Arg stimulates fibrinolysis (12). Finally, Arg may directly inhibit leukocyte adhesion to non-endothelial matrix independently of NO production (13), thereby inhibiting the development of atherosclerosis.

### Table 1

**Nitric oxide (NO)-dependent and independent vascular actions of L-arginine**

<table>
<thead>
<tr>
<th>NO-dependent vascular actions</th>
<th>NO-independent vascular actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smooth muscle cell relaxation</td>
<td>Polarization of EC membranes</td>
</tr>
<tr>
<td>EC proliferation and angiogenesis</td>
<td>Extracellular and intracellular pH</td>
</tr>
<tr>
<td>Endothelin-1 release</td>
<td>Release of insulin, GH, glucagon and prolactin</td>
</tr>
<tr>
<td>Leukocyte adhesion</td>
<td>Synthesis of urea, creatine, PRO and PA</td>
</tr>
<tr>
<td>Platelet aggregation</td>
<td>Plasmin generation and fibrinogenolysis</td>
</tr>
<tr>
<td>Superoxide production</td>
<td>Leukocyte adhesion to non-EC matrix</td>
</tr>
<tr>
<td>Expression of cell adhesion molecules</td>
<td>Blood viscosity</td>
</tr>
<tr>
<td>Expression of monocyte chemotactic peptides</td>
<td>Angiotensin-converting enzyme activity</td>
</tr>
<tr>
<td>Proliferation of smooth muscle cells</td>
<td>O₂⁻ release &amp; lipid peroxidation</td>
</tr>
<tr>
<td>EC apoptosis</td>
<td>Formation of TXB₂, fibrin and platelet-fibrin</td>
</tr>
</tbody>
</table>

1. Abbreviations: EC, endothelial cells; GH, growth hormone; PA, polyamines; PRO, proline; TXB₂, thromboxane B₂. The symbols ↑ and ↓ denote increase and decrease, respectively.

**Hypertension.** NO plays a crucial role in regulating blood pressure; thus, Arg or NO deficiency results in hypertension in animals and humans (3). Much research has shown that intravenous or oral Arg administration increases NO synthesis and prevents endothelial dysfunction in animal models of pulmonary hypertension or salt-induced hypertension (4). The same beneficial effect of Arg has been observed in most studies involving hypertensive patients, who exhibit elevated plasma levels of ADMA and reduced NO synthesis (4). For example, intravenous Arg infusion (0.5 g/kg body over 30 min) to infants with persistent pulmonary hypertension increases partial pressure of oxygen and systemic oxygenation within 90 min of the administration (20). Similarly, intravenous Arg infusion (0.525 g/kg body over 35 min) to infants with pul-
monary hypertension reduces pulmonary vascular resistance and enhances cardiac output (21). In contrast to some earlier reports (see Ref. 4 for review), recent studies have also demonstrated beneficial effects of Arg on essential hypertensive patients. For example, intravenous Arg infusion (20–30 g over 30 min) improves systemic and renal hemodynamics in salt-sensitive patients with essential hypertension (4), and intravenous Arg infusion (0.5 g/kg body over 30 min) reduces blood pressure and renal vascular resistance in essential hypertensive patients with normal or insufficient renal function (22).

**Diabetes.** Diabetes is associated with reduced plasma Arg concentrations (23), and thus Arg administration may become a promising solution to improve endothelial function in diabetic subjects. In support of this proposition, oral Arg administration (12.5 g/l in drinking water) to diabetic rats for 3 d reverses endothelial dysfunction, and an intravenous bolus of 3–5 g Arg reduces mean blood pressure and platelet aggregation in patients with noninsulin-dependent diabetes (23). A more recent study has shown that 4 wk of oral Arg supplementation (1.25 g/l in drinking water) to diabetic rats lowers blood pressure, restores the defective endothelium-dependent relaxation and decreases plasma levels of malondialdehyde (an indicator of oxidative stress) (24). Similarly, intravenous Arg infusion (30 g over 30 min) to newly diagnosed noninsulin-dependent diabetic patients reduces blood pressure and improves hemodynamic function (25).

**Obesity/insulin resistance.** Obesity/insulin resistance is associated with endothelial dysfunction, and recent studies have identified an important role for NO in the pathogenesis of insulin resistance. For example, insulin resistance at the level of the liver and peripheral tissues occurs in eNOS knock-out mice (26). Interestingly, intravenous Arg infusion (94 mg/kg body over 3 h) improves insulin sensitivity and insulin-mediated vasodilation in obese patients and in patients with non-insulin-dependent diabetes (27).

**Advanced age.** Aging is associated with decreases in plasma Arg concentrations and NO synthesis, and intravenous Arg infusion (0.56 g over 20 min) reverses the aging-associated endothelial dysfunction in humans (28). In a more recent study involving 1-y-old spontaneously hypertensive rats, Susic et al. (29) showed that 6 mo of oral Arg supplementation (1.2 g/l in drinking water) reduces arterial pressure and total peripheral resistance, diminishes left ventricular mass and improves coronary hemodynamics.

**L-Arginine Therapy for Cardiovascular Disorders.** Through enhancing NO production, restoring vasodilation and inhibiting the progression of atherosclerosis, Arg benefits patients with cardiovascular disorders. These disorders include coronary and peripheral arterial disease, ischemia/reperfusion injury and heart failure, all of which are associated with impaired NO synthesis and endothelial dysfunction (4).

**Coronary artery disease (CAD).** This disorder affects the arteries that supply blood to the heart muscle and is the major cause of heart attack. Systemic or oral Arg administration has been shown to improve cardiovascular function, increase exercise capacity and reduce myocardial ischemia in CAD patients (4). For example, an intravenous bolus of 30 g Arg to CAD patients normalizes coronary blood flow response to acetylcholine, and intracoronary infusion of 26 g Arg over 8 min induces coronary stenosis dilatation in CAD patients with chronic stable angina (4). In addition, oral Arg enhances brachial artery flow-mediated vasodilation and inhibits monocyte adhesion to EC in young men with CAD (30). Strikingly, 6 mo of oral Arg supplementation (9 g/d) decreases plasma endothelin-1 levels by 30% and increases coronary blood flow response to acetylcholine by 150% in nonobstructive CAD patients (31).

**Peripheral arterial disease (PAD).** This disorder results from the narrowing or blocking of peripheral arterial vessels in the legs and other parts of the body. Because damage to leg tissues is so severe in some cases as to result in gangrene and amputation, improving peripheral circulation will have tremendous impact in PAD patients. Interestingly, daily intravenous Arg infusion (12.6 g/d) for 7 d increases calf blood flow and enhances walking distance (32). Intravenous Arg infusion (30 g over 60 min) to PAD patients also increases NO synthesis and femoral artery blood flow (4). For hypercholesterolemic humans, oral daily consumption of Arg-enriched HeartBar (6.6 g Arg/d) for 2 wk increases pain-free and total walking distance by 66% and 23%, respectively, as well as quality of life in PAD patients (33).

**Ischemia/reperfusion.** NO plays an important role in regulating cerebral vascular tone and circulation, and thus NO deficiency contributes to large cerebral infarct size (34). Previous studies with animal models have shown that Arg administration improves tissue preservation during reperfusion and increases regional blood flow in focal cerebral ischemia (4). Addition of 3 mmol/L Arg to the perfusate of isolated rat hearts during hypoxia and reperfusion protects the myocardium against reoxygenation injury (35), suggesting that Arg supplementation to the cardioplegic solution may exert a cardioprotective effect. There is also evidence indicating that exogenous Arg protects hepatic, intestinal and lung microcirculation from ischemia/reperfusion injury (4). These findings may have important implications for cardioplegic arrest, organ transplantation and other surgeries requiring periods of ischemia or reperfusion.

**Heart failure.** Heart failure results from the heart’s inability to pump sufficient blood to maintain normal circulation. This often leads to congestive heart failure (CHF), in which blood and fluids accumulate in the lungs and elsewhere, causing congestion in the abdomen or legs. Heart failure is associated with decreased plasma Arg levels, increased plasma ADMA levels and reduced NO synthesis (4). There is increasing evidence indicating that systemic or oral Arg administration enhances forearm blood flow response to acetylcholine, decreases systemic vascular resistance and mean arterial pressure, and increases ventricular stroke volume and cardiac output (4). For example, 6 wk of oral Arg (5.6–12.6 g/d) reduces plasma levels of endothelin-1, increases forearm blood flow in response to exercise, and improves arterial compliance and overall functional status (36). Similarly, 4 wk of oral Arg (8 g/d) improves endothelium-dependent vasodilation in patients with heart failure, and this beneficial effect is additive with exercise training (37). In contrast to some earlier reports (see Ref. 4 for review), recent studies have demonstrated the beneficial effect of Arg on CHF patients. For example, 5 d of oral Arg (15 g/d) improves renal hemodynamics in CHF patients (38), and iv Arg infusion (30 g over 30 min) enhances cardiac performance in patients with severe CHF (39).

**Problems and Areas for Future Research.** Although intravenous Arg infusion (up to 0.5 g Arg-HCl/kg body for infants or 30 g Arg-HCl for adults over 30–60 min) or oral Arg (9 g Arg-HCl/d for adults) has little or no adverse effect on humans (20–22), higher oral doses of Arg-HCl are occasionally associated with nausea, stomach cramps and diarrhea (16,31,40). Possible causes may be excess NO production by the gastrointestinal tract and impaired intestinal absorption of other dietary basic amino acids (lysin and histidine). A solution to this potential problem may be the
alternative use of L-citrulline, an effective precursor for Arg synthesis (1). As a neutral amino acid, L-citrulline does not compete with basic amino acids for transport by cells, its conversion to Arg consumes 1 mol of ammonia in the form of aspartate and its administration does not require equimolar HCl. Thus, enteral or parenteral L-citrulline may be particularly useful for patients with elevated ammonia concentrations, impaired Arg transport or enhanced intestinal Arg catabolism. Recent, puzzling findings from some CAD patients reveal that elevating plasma Arg levels through oral Arg provision does not always increase vascular NO synthesis or availability (40). This underscores the need to understand the complexity of the mechanisms for the regulation of Arg metabolism and NO synthesis. Such work is necessary to fully explain the Arg paradox and some conflicting findings regarding the effects of Arg on the vascular system (40). Third, because of the lack of published reports, much research will be required to evaluate the role for oral Arg or L-citrulline in reversing endothelial dysfunction associated with smoking, hypertension, diabetes, obesity/insulin resistance, aging and pre-eclampsia in humans. Collectively, these studies will help establish dietary Arg or L-citrulline supplementation as a potentially novel nutritional strategy for preventing and treating cardiovascular disorders.

LITERATURE CITED